Savara Inc. (SVRA) is a clinical-stage biopharmaceutical company based in Austin, Texas, focused on rare respiratory diseases. Its lead asset is molgramostim inhalation solution, an inhaled form of granulocyte-macrophage colony-stimulating factor being developed for autoimmune pulmonary alveolar proteinosis, a rare lung disorder with no approved pharmacologic therapy in the United States. The company has no product revenue.
Shares traded at $4.93 at midday, up $0.21 or 4.45%, from the prior session's close of $4.72. The stock is higher for a second consecutive session, having gained 5.36% on Wednesday. Direction is unambiguously upward, and the advance comes with no company-specific announcement: the immediate reason cited across the market is investor positioning into the FDA's November 22 target action date for molgramostim.
Savara's entire equity story now rests on a single regulatory decision. The FDA's review of the molgramostim marketing application was extended by three months after the company submitted a major amendment, and action is now expected by November 22. That timeline leaves investors weighing a binary outcome: approval would create the first approved therapy for aPAP and unlock commercial launch, while a complete response letter would sharply reset the valuation.
Because the date is fixed and publicly known, buying pressure typically builds in the sessions immediately before it, particularly in names with heavy short interest. Wednesday's 5.36% gain and today's follow-through fit that pattern of pre-event accumulation rather than reaction to new information. The move also reverses a three-session slide that took the stock to $4.48 on November 17.
Trading activity is the clearest confirmation of conviction behind the advance. Roughly 5.8 million shares have changed hands, more than four times the 60-day average of about 1.4 million, with two large block prints standing out during the morning. Such concentrated volume is consistent with institutional repositioning ahead of a scheduled catalyst.
Short interest adds fuel. More than 32 million shares were reported short as of the mid-October settlement date, equal to over 12 days of average trading volume. Any favorable headline, or simply continued buying into the event, forces covering that can magnify an otherwise ordinary gain.
Research coverage has been supportive. JPMorgan initiated at Overweight with a $12 price target in early October, and the broader consensus sits near $10, well above current levels. Third-quarter results released November 9 showed a net loss of $43 million, research and development expense of $25 million and general and administrative expense of $19 million, the latter up sharply as the company builds commercial infrastructure.
Savara ended September with about $130 million in cash and short-term investments against nine-month operating burn of roughly $105 million. An additional $150 million of contingent financing—$75 million from RTW Investments and up to $75 million in Hercules term loans—becomes available only if approval arrives by March 31, 2027, tying the balance sheet directly to the regulatory outcome.
The gain was company-specific rather than sector-wide. Small-cap biotechnology peers traded mixed and largely directionless, and today's buying was concentrated in Savara rather than spread across the group. That divergence supports an event-driven interpretation over macro or sector momentum.
Technically, the stock opened near $4.81, sold off briefly toward $4.73, then broke higher through the $4.90 area and touched roughly $5.14 before paring gains—the highest intraday level since November 11. That push stalled just above the $5.05–$5.15 band that capped the stock earlier in November, leaving the $5.00 level as near-term support that bulls will want to hold. Even after the two-day run, shares remain well below their 52-week high of $7.01 and comfortably above the $4.13 low.
On a scale where 0 means no meaningful news and a move that is normal for the stock, and 100 means transformative news paired with an extreme, rare price move, this session scores 28 out of 100. The verified news backdrop is thin: no release, filing or rating change accompanied the gain, and the catalyst is a scheduled regulatory date rather than a new disclosure.
The price behavior was also unremarkable by Savara's own standards. Today's 4.45% advance is roughly 1.6 times the stock's typical daily move of about 2.7%, and 13 of the last 60 sessions produced swings of equal or greater size. A modest catalyst and a routine-sized move combine into a low-to-moderate score.
The decisive variable is the FDA's action on molgramostim, expected by November 22. Beyond the verdict itself, investors will focus on the approved label's scope, any post-marketing requirements, and the company's readiness to launch—including payer conversations and the size of the aPAP patient population it can reach. Management has guided toward building a commercial organization, and the pace of that spend will determine how far existing cash extends.
Key risks are asymmetric and well documented: a delay or negative decision would remove the sole near-term value driver, while the contingent financing package remains contingent on timely approval. Savara carries no product revenue and depends on capital markets if the timeline slips. On the positive side, supportive analyst coverage and a heavily shorted float could extend volatility in either direction once the decision is known.
Tickeron's Trending AI Robots page is a curated view of the platform's strongest performers under current market conditions, drawn from a library of hundreds of AI trading bots covering thousands of tickers. Bots differ widely in strategy, holding period, performance metrics and the symbols they trade, so the featured list highlights only those posting the most consistent results right now. For traders navigating event-driven names like this one, it offers a useful, data-driven starting point for further review.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
The RSI Oscillator for SVRA moved out of oversold territory on October 26, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 19 similar instances when the indicator left oversold territory. In 16 of the 19 cases the stock moved higher. This puts the odds of a move higher at 84%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Momentum Indicator moved above the 0 level on November 18, 2026. You may want to consider a long position or call options on SVRA as a result. In 71 of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 72%.
Following a +5.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where SVRA advanced for three days, in 191 of 242 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
SVRA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Moving Average Convergence Divergence Histogram (MACD) for SVRA turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 35 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.
SVRA moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SVRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for SVRA entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 31 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 45 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Seasonality Score of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. SVRA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.908) is normal, around the industry mean (3.592). P/E Ratio (-8.328) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a pharmaceuticals developer
Industry Biotechnology